Company Overview and News
KUALA LUMPUR, April 10 — Bursa Malaysia reversed its gains momentum to open mixed this morning on weak sentiment following the retreat on Wall Street’s overnight performance.
STEEL products manufacturer Tatt Giap Group Bhd said earlier this week that it planned to venture into property development after a lack of favourable prospects in the steel industry and a challenging business environment continued to pull the loss-making firm down.
Market breadth was positive as gainers outpaced losers 420 to 369, with 375 counters unchanged, 712 untraded and 21 others suspended. — Bernama picKUALA LUMPUR, March 9 — Shares on Bursa Malaysia ended the morning session higher, driven by an improved market sentiment following overnight gains in Asian equities and strong China trade data.
At 11am, the FTSE Bursa Malaysia KLCI (FBM KLCI) was 2.84 points better at 1,842.46 from 1,839.62 at yesterday's close. — Picture by Azneal IshakKUALA LUMPUR, March 9 ― Shares on Bursa Malaysia remained higher at mid-morning today on improved market sentiment following overnight gains in Asian equities and strong China trade data.
At 9.15am, the benchmark FTSE Bursa Malaysia KLCI (FBM KLCI) stood at 1,844.56, up 4.94 points from 1,839.62 at yesterday's close. — Picture by Azneal IshakKUALA LUMPUR, March 9 ― Shares on Bursa Malaysia opened higher this morning, with market sentiment lifted by overnight gains in Asian equities and strong China trade data.
A view of the bursa stock market exchange board in RHB Investment Bank in Kuala Lumpur February 6, 2018. — Picture Ahmad ZamzahuriKUALA LUMPUR, Feb 14 — Bursa Malaysia ended the morning session higher as investor sentiment perked over the release of better-than-expected 2017 fourth quarter and full year gross domestic product (GDP) data for the country.
Bursa Malaysia resumed afternoon session on a easier note, reversing its earlier gains on the back of weak buying momentum especially for bluechips in Kuala Lumpur June 29, 2017. — Bernama picKUALA LUMPUR, Feb 14 — Trading on Bursa Malaysia was range bound at mid-morning as investors were cautious ahead of the release of gross domestic product (GDP) data for the fourth quarter of 2017 and for the full year by Bank Negara later this afternoon.
KUALA LUMPUR, Feb 12 — Bursa Malaysia stayed higher at mid-morning on continued buying interest in selected heavyweights led by Axiata, CIMB and Maxis.
KUALA LUMPUR, Jan 26 — Bursa Malaysia opened slightly lower on profit-taking activities among investors and especially in finance stocks, a dealer said.
KUALA LUMPUR, Jan 23 — Bursa Malaysia closed higher today on the back of buying support in penny stocks, as well as big capital stocks.
Gainers outpaced losers 220 to 85, while 238 counters were unchanged, 1,305 untraded and 31 others suspended. — Bernama picKUALA LUMPUR, Jan 23 — Shares on Bursa Malaysia were higher at today’s opening on buying support, a dealer said.
KUALA LUMPUR: LPI Capital Bhd , Ewein Bhd , My EG Services Bhd (MyEG), Tan Chong Motor Holdings Bhd are among the stocks to watch on Thursday, according to JF Apex Research.
KUALA LUMPUR, Oct 11 — Bursa Malaysia ended lower today, dragged down by selling in blue-chips led by Genting and telecommunication stocks, as well as in line with the performance of most Southeast Asian peers, dealers said.
KUALA LUMPUR, Oct 11 — Bursa Malaysia trended lower at mid-afternoon today, as selling in bluechips led by Genting and telecommunication stocks continued to drag down the barometer index, dealers said.
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...